DDInter1711 DDInter1676
Stiripentol is an antiepileptic agent that is an aromatic allylic alcohol drug, which makes it structurally unique from other antiepileptic drugs.[A19740, A250825] The clinical development and marketing of stiripentol were first delayed due to the drug's potent inhibitory effects on hepatic cytochrome P450 (CYP) enzymes. However, its clinical efficacy as adjunctive therapy for epilepsies stems from its inhibitory action on CYP enzymes, as stiripentol reduces the degradation of CYP-sensitive antiepileptic drugs, hence boosting their therapeutic efficacy. Stiripentol may also exhibit direct anticonvulsant properties, although the exact mechanism of action is fully understood. Approved in the US, Canada, and Europe, stiripentol is used to treat seizures associated with Dravet syndrome.[L880,L42500,L42510] It is marketed under the brand name Diacomit.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Stiripentol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Stiripentol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apixaban
Stiripentol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fedratinib
Stiripentol {u} may lead to a major life threatening interaction when taken with {v} Venetoclax
Stiripentol {u} may lead to a major life threatening interaction when taken with {v} Naloxegol
Stiripentol may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Stiripentol may cause a moderate interaction that could exacerbate diseases when taken with Apixaban
Stiripentol may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Stiripentol may lead to a major life threatening interaction when taken with Venetoclax
Stiripentol may lead to a major life threatening interaction when taken with Naloxegol